4592
SanBio Company Limited
サンバイオ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(-)
Jan 2022
-
Jan 2023
-
Jan 2024
-
Jan 2025
-
Jan 2026
-
Operating profit(thousand JPY)
Jan 2022
-6,620,884
Jan 2023
-7,899,308
Jan 2024
-4,539,730
Jan 2025
-3,516,093
Jan 2026
-3,794,811
Operating profit margin(-)
Jan 2022
-
Jan 2023
-
Jan 2024
-
Jan 2025
-
Jan 2026
-
Profit before tax(thousand JPY)
Jan 2022
-4,560,423
Jan 2023
-4,697,443
Jan 2024
-2,542,135
Jan 2025
-3,010,666
Jan 2026
-4,291,743
Profit(thousand JPY)
Jan 2022
-4,677,856
Jan 2023
-5,559,584
Jan 2024
-2,644,332
Jan 2025
-2,882,885
Jan 2026
-3,842,612
Total assets(thousand JPY)
Jan 2022
5,510,901
Jan 2023
7,045,114
Jan 2024
5,047,291
Jan 2025
3,447,339
Jan 2026
15,621,539
Cash and cash equivalents(thousand JPY)
Jan 2022
4,557,006
Jan 2023
6,675,198
Jan 2024
4,389,520
Jan 2025
2,853,132
Jan 2026
14,815,273
Cash flows from operating activities(thousand JPY)
Jan 2022
-6,546,664
Jan 2023
-7,434,147
Jan 2024
-4,765,654
Jan 2025
-3,603,106
Jan 2026
-3,760,890
Cash flows from investing activities(thousand JPY)
Jan 2022
-66,261
Jan 2023
-10,100
Jan 2024
-19,028
Jan 2025
-4,267
Jan 2026
-231,044
Cash flows from financing activities(thousand JPY)
Jan 2022
-1,495,484
Jan 2023
9,445,783
Jan 2024
2,370,532
Jan 2025
2,091,005
Jan 2026
15,962,690
Return on equity(-)
Jan 2022
-
Jan 2023
-
Jan 2024
-
Jan 2025
-
Jan 2026
-
Equity ratio(%)
Jan 2022
31
Jan 2023
56.5
Jan 2024
51.3
Jan 2025
45.1
Jan 2026
85.4
Earnings per share(JPY per share)
Jan 2022
-90.33
Jan 2023
-95.99
Jan 2024
-40.48
Jan 2025
-41.86
Jan 2026
-52.55
Net assets per share(JPY per share)
Jan 2022
32.99
Jan 2023
62.12
Jan 2024
38.08
Jan 2025
21.93
Jan 2026
170.93
Dividend per share(-)
Jan 2022
-
Jan 2023
-
Jan 2024
-
Jan 2025
-
Jan 2026
-
Payout ratio(-)
Jan 2022
-
Jan 2023
-
Jan 2024
-
Jan 2025
-
Jan 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.